GlaxoSmithKline (GSK) has begun the sale of some of its consumer health brands ... Boutique investment bank Greenhill is to market the products to separate bidders, three anonymous sources ...
GlaxoSmithKline has announced its second major deal this month, signing an agreement with Pfizer to combine its consumer health business ... largest over-the-counter products firm in the world ...
GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...
We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against other undervalued defensive Stocks for ...
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...
J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback